Table 4 Results of Logistic Regression Model.

From: A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database

 

Logistics regression

Univariate

Multivariate†

Variable

OR (95%CI)

P-value

OR (95%CI)

P-value

Gender

 

  Female

1(ref)

1(ref)

  Male

1.29(1.12–1.49)

 < 0.001

1.23(1.06–1.43)

0.006

Age

 

   < 18

1(ref)

1(ref)

  18–65

0.75(0.61–0.93)

0.008

1(0.78–1.28)

0.976

   > 65

1.41(1.10–1.82)

0.008

1.75(1.32–2.31)

 < 0.001

Weight

 

   < 50 kg

1(ref)

1(ref)

  50–100 kg

0.60(0.48–0.75)

 < 0.001

0.59(0.46–0.76)

 < 0.001

   > 100 kg

0.57(0.44–0.73)

 < 0.001

0.56(0.42–0.75)

 < 0.001

Time

  

   < 180 days

1(ref)

1(ref)

  180–360 days

1.08(0.87–1.34)

0.494

1.07(0.86–1.33)

0.544

   > 360 days

1.40(1.20–1.64)

 < 0.001

1.38(1.18–1.62)

 < 0.001

  1. †Three variables in addition to the independent variables are used as covariates to adjust.
Back to article page